STOCK TITAN
  1. Home
  2. Sec-filings
  3. MXCT
  4. [Form 4] MAXCYTE, INC. Insider Trading Activity

MAXCYTE (MXCT) director Cynthia Collins receives RSUs and 49,579-share option grant

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

MAXCYTE director Cynthia Collins received new equity awards. On June 17, 2026, she was granted 30,421 restricted stock units, each representing one future share of common stock, and a stock option for 49,579 shares at an exercise price of $1.13 per share, expiring in 2036. Following the grant, she directly holds 111,310 shares of common stock, and the RSUs vest on June 17, 2027 if she continues serving as a director.

Positive

  • None.

Negative

  • None.
Insider Collins Cynthia
Role null
Type Security Shares Price Value
Grant/Award Stock Option (right to buy) 49,579 $0.00 --
Grant/Award Common Stock 30,421 $0.00 --
Holdings After Transaction: Stock Option (right to buy) — 49,579 shares (Direct, null); Common Stock — 111,310 shares (Direct, null)
Footnotes (1)
  1. These shares represent restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. This annual grant was made pursuant to the Issuer's Equity Grant Policy for non-employee directors. The shares underlying this grant vest on June 17, 2027, subject to the reporting person's continuous service as of such vesting date.
RSU grant size 30,421 RSUs Annual grant to non-employee director on June 17, 2026
Stock options granted 49,579 options Right to buy MAXCYTE common stock
Option exercise price $1.13 per share Conversion or exercise price for 49,579 options
Option expiration June 16, 2036 Expiration date of stock option grant
Shares held after grant 111,310 shares Common stock directly owned following transactions
restricted stock units ("RSUs") financial
"These shares represent restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share..."
Restricted stock units (RSUs) are a company promise to give an employee shares of stock (or cash equivalent) in the future, but only after certain conditions—usually staying with the company for a set time or hitting performance goals—are met. Investors watch RSUs because when they vest they increase the number of shares outstanding and can lead insiders to sell shares, affecting share price, company dilution and the true cost of employee pay.
Equity Grant Policy financial
"This annual grant was made pursuant to the Issuer's Equity Grant Policy for non-employee directors."
Stock Option (right to buy) financial
"Stock Option (right to buy) ... conversion_or_exercise_price: "1.1300""
vesting financial
"The shares underlying this grant vest on June 17, 2027, subject to the reporting person's continuous service..."
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Collins Cynthia
(Last)(First)(Middle)
C/O MAXCYTE, INC.
9713 KEY WEST AVENUE, SUITE 400
(Street)
ROCKVILLE MARYLAND 20850
(City)(State)(Zip)
UNITED STATES
(Country)		2. Issuer Name and Ticker or Trading Symbol
MAXCYTE, INC. [ MXCT ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
06/17/2026		6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock06/17/2026A30,421(1)(2)A$0111,310D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Option (right to buy)$1.1306/17/2026A49,579 (2)06/16/2036Common Stock49,579$049,579D
Explanation of Responses:
1. These shares represent restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock.
2. This annual grant was made pursuant to the Issuer's Equity Grant Policy for non-employee directors. The shares underlying this grant vest on June 17, 2027, subject to the reporting person's continuous service as of such vesting date.
/s/ Maher Masoud, Attorney-in-Fact06/22/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What equity awards did MAXCYTE (MXCT) director Cynthia Collins receive?

Cynthia Collins received 30,421 restricted stock units and a stock option for 49,579 shares. The option has a $1.13 exercise price and expires in 2036, aligning her compensation with MAXCYTE’s long-term performance.

Are Cynthia Collins’ new MAXCYTE RSUs immediately vested?

No, the 30,421 restricted stock units vest on June 17, 2027. Vesting is conditional on her continuous service as a non-employee director, encouraging longer-term board commitment and alignment with shareholders’ interests over time.

What is the exercise price and term of Cynthia Collins’ MAXCYTE stock options?

Her stock option covers 49,579 shares of MAXCYTE common stock at a $1.13 exercise price. The option expires on June 16, 2036, providing a long-dated incentive tied to potential future share price appreciation.

How many MAXCYTE shares does Cynthia Collins hold after these grants?

After the June 17, 2026 grants, Cynthia Collins directly holds 111,310 shares of MAXCYTE common stock. This reflects her ongoing equity stake in the company in addition to the new RSUs and stock option award.

Why did MAXCYTE grant these awards to Cynthia Collins?

The awards were made under MAXCYTE’s Equity Grant Policy for non-employee directors. This policy provides annual equity grants, using RSUs and options to compensate directors and better align their interests with company shareholders.